Lyell Immunopharma, Inc. (LYEL) has a consensus analyst rating of Hold, based on 5 analysts covering the stock. Of those, 1 recommend buying, 3 recommend holding, and 1 recommend selling.
The analyst consensus price target for LYEL is $45.00, representing a +92.6% upside from the current price of $23.37. Price targets range from a low of $45.00 to a high of $45.00.
